Patients with cancer who received an mRNA-based COVID vaccine within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years later, according to new research presented at a major cancer conference. The finding, which earned lead researcher Dr. Adam Grippin recognition as a NextGen Star, adds to growing evidence that certain vaccines may help prime the immune system to better respond to cancer treatments.
The study, drawn from previously published data, examined patients who began immune checkpoint inhibitors within 100 days of receiving an mRNA COVID vaccine. Those patients showed a significant survival advantage at three years compared to patients who did not receive the vaccine near the start of therapy. Researchers are now exploring whether this effect can be harnessed more broadly, potentially using mRNA technology to boost responses to existing cancer immunotherapies.
In a separate study, researchers developed a first-in-class platform called NK-TCR that combines natural killer cells with T cell receptors to target antigens hidden inside tumor cells. In models of multiple myeloma, the approach showed strong antitumor activity with low safety risk. The platform targets the NY-ESO-1 and PRAME tumor antigens, and investigations are expanding into other cancer types.
Another team used artificial intelligence to target the protein GRB2, long considered undruggable, to overcome resistance to PARP inhibitors. By creating a small molecule that locks GRB2 in its inactive state, researchers enhanced sensitivity to PARP inhibitors and exposed cancer cells to immune detection. The approach could offer a new strategy for patients whose tumors have stopped responding to standard treatments.
New Tools for Earlier Detection and Personalized Treatment
For pancreatic cancer, researchers identified a predictive biomarker in patients with new-onset diabetes. Analyzing samples from 2,121 patients, they found that CA19-9 trajectories could signal underlying pancreatic cancer, offering a potential early warning system for a disease often caught too late. In thyroid cancer, a new gene signature called PRECISE was developed using single-cell technology and a patient cohort with a median follow-up of 14 years to better predict which tumors will lead to poorer outcomes.
Researchers also unveiled OncoTwin, an AI-driven digital twin model that predicts individual treatment response in ALK-positive lung cancer. By simulating how a patient’s unique tumor biology will react to tyrosine kinase inhibitors, the model could guide clinical trial design and help doctors choose alternative therapies when standard drugs are unlikely to work.
These studies, among more than a dozen presented at the meeting, point to a future where cancer care is increasingly guided by molecular insights, AI-powered predictions, and immune-based strategies. While many of the findings are early, researchers expressed optimism that the combination of advanced technologies and deeper biological understanding will translate into more effective, personalized treatments for patients in the years ahead.